Kristy Williams
Nurse Practitioner · Madison, ALNPI 1447798616
Payments from drug & device makers
Across 228 payments — averaging $14.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$870
- Novo Nordisk$552
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$308
- AstraZeneca$296
- Lilly USA, LLC$251
- Amgen$198
- plus $866 from 18 others
What the payments were for
- Food & beverage$3,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $870 |
| Novo Nordisk | 48 | $552 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $308 |
| AstraZeneca | 17 | $296 |
| Lilly USA, LLC | 15 | $251 |
| Amgen | 12 | $198 |
| Pfizer | 9 | $154 |
| GSK | 8 | $125 |
| Boehringer Ingelheim | 6 | $93 |
| Exact Sciences | 4 | $67 |
| Astellas Pharma US Inc | 4 | $65 |
| Bayer | 4 | $60 |
| Mylan Specialty L.p. | 3 | $50 |
| Daiichi Sankyo Inc. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $47 |
| Eisai Inc. | 2 | $25 |
| Johnson & Johnson | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Scynexis, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Corium, LLC | 1 | $15 |
| Merck | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $11 |
How this compares
$3,340 in reported general payments places this provider in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 18 | $26,176 |
| OzempicSemaglutide | 23 | $26,157 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $18,667 |
| FarxigaDapagliflozin Propanediol | 11 | $12,898 |
| Rosuvastatin Calcium | 122 | $2,209 |
| Levothyroxine Sodium | 79 | $850 |
| Atorvastatin Calcium | 86 | $841 |
| Omeprazole | 50 | $824 |
| Pravastatin Sodium | 29 | $708 |
| Losartan Potassium | 59 | $703 |
| Amlodipine Besylate | 84 | $670 |
| Lisinopril | 70 | $506 |
| Metformin Hcl ErMetformin Hcl | 39 | $459 |
| Fenofibrate | 18 | $428 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $421 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $93 | $26,17618 claims |
| Novo NordiskOzempic | $552 | $26,15723 claims |
| MerckJanumet | $14 | $18,66711 claims |
| AstraZenecaFarxiga | $296 | $12,89811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,505 nurse practitioner providers in Alabama.
Other nurse practitioner in Madison
- Erin TannerAlabaster$141K
- Ardie Pack MabienMobile$126K
- Ginger McDanielBirmingham$27K
- Audrey MorganMontgomery$24K
- Hollie CrutchfieldDothan$22K
- Leah GravesBirmingham$21K
- Lauren DowneyBirmingham$19K
- Ashley HodgensMontgomery$19K
- Lisa PeoplesBirmingham$17K
- Samantha WeaverBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.